Small Molecule Drug Discovery Global Market 2024 - Top Regions, Latest Technology, Investment Opportunities, Future Trends And Outlook 2033

The new report published by The Business Research Company, titled ""Small Molecule Drug Discovery Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the small molecule drug discovery market size has grown strongly in recent years. It will grow from $57.41 billion in 2023 to $63.15 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The small molecule drug discovery market size is expected to see rapid growth in the next few years. It will grow to $95.63 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9834&type=smp

Chronic Disease Surge Propels Growth In Small Molecule Drug Discovery Market
The rising incidence of chronic diseases is expected to boost the growth of the small molecule drug discovery market going forward. Chronic diseases refer to conditions that last for a year or longer, hinder everyday activities, demand continuous medical care, or both. Small-molecule medications can be used to treat chronic conditions like HIV, cancer, infections, heart disease, and renal disease, and these medications are generally more economical for patients with chronic conditions. Hence, the rising incidence of chronic diseases is expected to boost the small molecule drug discovery market. For instance, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, in 2023, in the United States, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity would rise by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the rising incidence of chronic diseases is driving the growth of the small molecule drug discovery market.

Small Molecule Drug Discovery Market Thrives On Technological Innovations
Technological innovations are the key trend gaining popularity in the small molecule drug discovery market. Major companies operating in the small molecule drug discovery market are focusing on developing new products. For instance, in January 2023, Dotmatics, a US-based provider of digital science platform, launched Small Molecule Drug Discovery Solution. It is uniquely designed with integrated scientific R&D platform that has pre-configured workflows and expanded data management capabilities. It reduces the operational inefficiencies, and speeds the process of taking data from insights to decisions.

The small molecule drug discovery market covered in this report is segmented -

1) By Drug Type: Small Molecule Drugs, Biologic Drugs
2) By Technology: High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, Others
3) By Therapeutic Area: Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal, Others
4) By Process/Phase: Target ID Or Validation, Hit Generation And Selection, Lead Identification, Lead Optimization
5) By End-User: Pharmaceutical Companies, Contract Research Organizations, Others

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9834&type=discount

Major companies operating in the small molecule drug discovery market report are Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, Gilead Sciences Inc., Merck KGaA, Novartis AG, 21st Century Therapeutics Inc., 4SC AG, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Immunocure Inc., Labcorp Drug Development, ICON Public Limited Company, Charles River Laboratories, Aluda Pharmaceuticals, CelerisTx, Clinuvel Pharmaceuticals, Corcept Therapeutics, Doloromics, Edison Oncology, Escend Pharmaceuticals, Terray Therapeutics, Apollomics, Astex Pharmaceuticals, Surface Ophthalmics, Pardes Biosciences, Xynomic Pharmaceuticals, AfaSci, Zevra Therapeutics, Saniona, UNION therapeutics, Tetra Pharm Technologies, Pharmacosmos, Allarity Therapeutics, Xellia Pharmaceuticals, Cyteir Therapeutics, BigHat Biosciences .

Contents of the report:
1. Executive Summary
2. Small Molecule Drug Discovery Market Report Structure
3. Small Molecule Drug Discovery Market Trends And Strategies
4. Small Molecule Drug Discovery Market - Macro Economic Scenario
5. Small Molecule Drug Discovery Market Size And Growth
…..
27. Small Molecule Drug Discovery Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.